Advances in molecular-targeted therapy for unresectable pancreatic cancer
- VernacularTitle:不可切除胰腺癌的分子靶向药物治疗进展
- Author:
Run HU
1
;
Junen LI
1
;
Pei YAO
1
;
Renjie GUI
1
;
Huaxin DUAN
1
Author Information
- Publication Type:Review
- Keywords: Pancreatic Neoplasms; Molecular Targeted Therapy; Immunotherapy
- From: Journal of Clinical Hepatology 2024;40(2):426-432
- CountryChina
- Language:Chinese
- Abstract: Pancreatic cancer is one of the most prevalent malignant tumors of the digestive system， and its incidence and mortality rates are increasing year by year. Most patients with pancreatic cancer are unable to receive surgery due to the advanced stage. Although chemotherapy regimens based on gemcitabine and fluorouracil have prolonged the survival time of patients to some extent， some patients cannot tolerate chemotherapy and hence lose the opportunity for treatment. With the advent of the era of precision medicine， molecular-targeted therapy has exhibited an excellent therapeutic efficacy and has thus become one of the most important treatment techniques for tumors； however， due to the high heterogeneity of pancreatic cancer and its complicated tumor microenvironment， molecular-targeted therapy for pancreatic cancer has not achieved notable results. Therefore， it is imperative to seek new therapeutic targets and medications to overcome this issue. This article reviews the latest advances in the research on molecular-targeted therapy for unresectable pancreatic cancer based on common molecular targets and tumor immunity-related therapeutic targets， in order to provide new treatment strategies for patients with pancreatic cancer.
